| Examiner | Number of Cases | 3YGR |
|---|---|---|
| Examiner Allen (SPE) | 278 | 26% |
| Examiner Barrera | 14 | 0% |
| Examiner Bellecourt | 0 | 0% |
| Examiner Blumel | 410 | 75% |
| Examiner Foley | 390 | 78% |
| Examiner Gill | 508 | 67% |
| Examiner Hill | 288 | 70% |
| Examiner Li | 342 | 78% |
| Examiner Ly | 1 | 0% |
| Examiner Parkin | 336 | 61% |
| Examiner Sifford | 56 | 27% |
| Examiner Zou | 413 | 72% |
| Art Unit 1671 | 3036 | 66% |
| Number | Class Description |
|---|---|
| 424 | Drug, bio-affecting and body treating compositions |
| 435 | Chemistry: molecular biology and microbiology |
| 702 | Data processing: measuring, calibrating, or testing |
| 568 | Organic compounds -- part of the class 532-570 series |
| 514 | Drug, bio-affecting and body treating compositions |
| 562 | Organic compounds -- part of the class 532-570 series |
| 560 | Organic compounds -- part of the class 532-570 series |
| 554 | Organic compounds -- part of the class 532-570 series |
| 570 | Organic compounds -- part of the class 532-570 series |
| 564 | Organic compounds -- part of the class 532-570 series |
Art Unit 1671's grant rate is higher than that of Group 1670 and lower than that of the USPTO.
Below is the grant rate timeline for Art Unit 1671, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.